Genetically-informed therapy for advanced ER+ breast cancer after CDK4/6 inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of specific drug combinations in treating post-menopausal women with advanced ER+/HER2- breast cancer who have previously been treated with CDK4/6 inhibitors such as palbociclib, ribociclib, or abemaciclib. The interventions include Fulvestrant, Neratinib, Alpelisib, Everolimus, and Abemaciclib, focusing on patients with metastatic or locally recurrent disease not suitable for curative treatment. The study will assess the response to these therapies to determine their potential benefits in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Post-menopausal women ≥18 years of age with metastatic ER+ breast cancer, or with locally recurrent ER+ disease not amenable to therapy for curative intent.
2. Patient must be post-menopausal per NCCN guidelines.
3. Patient must have been treated with a CDK4/6i (either palbobclib, ribociclib, or abemaciclib) alone or in combination with an endocrine agent in the advanced disease setting.

   * Up to 3 lines of therapy following CDK4/6i are permissible.
   * Any number of prior lines of endocrine-containing therapy is permissible.
   * Up to 1 prior line of chemotherapy is permissible.
4. Histologic documentation of ER+ breast cancer by core needle biopsy, fine needle aspiration, incisional biopsy, or surgical biopsy of ≥1 site(s) of metastatic or locally recurrent disease performed as standard of care.

   * Exceptions: patients with bone-dominant metastatic disease, or non-bone metastatic disease in whom a safe and accurate biopsy of recurrent/metastatic disease cannot be readily obtained, with a history of ER+ breast cancer are eligible, and biopsy is not required, providing their primary cancer is consistent with the ER criteria described below.
5. ER+ status defined as ER staining by immunohistochemistry in ≥1% of malignant cell nuclei.
6. Tumor must be HER2-non-amplified as defined by an immunohistochemistry score of 0-1+, or with a FISH ratio \<2 if IHC is 2+ or if IHC has not been done (as per ASCO/CAP definitions). In cases of borderline or equivocal HER2 status, eligibility will be determined by the PI.
7. Genetic profiling of a tumor or plasma specimen acquired after disease progression on a CDK4/6i must have been performed in a CAP-accredited, CLIA-certified laboratory using clinically validated methods. Profiling must minimally include analysis of study-relevant alterations in ERBB2, PIK3CA, AKT1, MTOR, PTEN, and RB1.

   * If not done: Profiling of a tumor (preferable) or plasma specimen will be performed as part of the study in the DHMC Pathology Laboratory. A plasma specimen may be obtained for study-specific genetic profiling to direct treatment assignment. Tumor specimens must be obtained outside of this study (e.g., by biopsy).
8. If available, archived tumor tissue must be accessible for research purposes, sufficient to make ≥10 five-micron sections; more tumor tissue is preferred.
9. Radiographic staging performed as standard of care, including specifically either PET/CT, or contrast CT (CAP) and bone scan.
10. Patient must be capable and willing to provide informed written consent for study participation.

Exclusion Criteria:

1. Treatment with abemaciclib in the most recent or current line of therapy.
2. During the study Treatment Phases, no concurrent anti-cancer therapies are allowed with the following exception: anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.
3. Any investigational cancer therapy in the last 3 weeks.
4. Known untreated CNS disease, unless clinically stable for ≥ 3 months.

Where it's running

• Dartmouth Hitchcock Medical Center
  Lebanon, New Hampshire, United States Recruiting

Study contacts

• Principal investigator: Mary Chamberlin, MD — Dartmouth-Hitchcock Medical Center
• Study coordinator: Research Nurse
• Email: hem-onc.research.nurses@hitchcock.org
• Phone: 603-650-5021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

• Timing ctDNA Testing to Guide Treatment in Advanced Breast Cancer

  This study tests how ctDNA levels and key gene mutations relate to outcomes and treatment responses in adults with advanced breast cancer.

  Recruiting Geneplus-Beijing Co. Ltd. · Beijing · NCT07681323

• Decision Support Tool for People with Advanced Breast Cancer

  This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.

  Recruiting at 3 sites Weill Medical College of Cornell University · Brooklyn, New York and 2 other locations · NCT07635147

• Metronomic Oral Paclitaxel for Advanced HER2-Negative Breast Cancer

  This study tests whether low, regular doses of an oral paclitaxel solution can be safely used to control tumor growth in adults with advanced HER2-negative breast cancer who have already had prior cancer therapy.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07602907

• Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression

  This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.

  Recruiting Phase 4 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07600164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.